Yuhei Shibata

ORCID: 0000-0003-2040-8903
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Acute Myeloid Leukemia Research
  • Tryptophan and brain disorders
  • Viral-associated cancers and disorders
  • Childhood Cancer Survivors' Quality of Life
  • Acute Lymphoblastic Leukemia research
  • T-cell and Retrovirus Studies
  • Multiple Myeloma Research and Treatments
  • Hematological disorders and diagnostics
  • Nutrition and Health in Aging
  • Neutropenia and Cancer Infections
  • Bone health and treatments
  • Cancer, Hypoxia, and Metabolism
  • Bipolar Disorder and Treatment
  • Lung Cancer Treatments and Mutations
  • Adolescent and Pediatric Healthcare
  • Bone and Joint Diseases
  • Cancer Research and Treatments
  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Musculoskeletal synovial abnormalities and treatments
  • Systemic Sclerosis and Related Diseases

Gifu Municipal Hospital
2017-2024

Tonan Hospital
2023

National Institute of Technology, Tomakomai College
2020-2021

Shimizu (Japan)
2021

Gifu University
2005-2019

Hokkaido University
2017-2019

Obihiro Kosei General Hospital
2016

Azacitidine is a mainstay of therapy for myelodysplastic syndrome (MDS)-related diseases. The purpose our study to elucidate the effect gene mutations on hematological response and overall survival (OS), particularly focusing their posttreatment clone size. We enrolled total 449 patients with MDS or related myeloid neoplasms. They were analyzed in pretreatment (n = 449) 289) bone marrow samples using targeted-capture sequencing assess impact size treatment outcomes. In Cox proportional...

10.1182/bloodadvances.2022009564 article EN cc-by-nc-nd Blood Advances 2023-03-29

The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability catalyze breakdown the essential amino acid L-tryptophan. We applied reverse transcription-polymerase chain reaction (RT-PCR) examine IDO mRNA expression in acute myeloid leukemia (AML) blasts, and investigated clinical significance. enrolled 62 patients with AML between April 2005 March 2013. Bone marrow-derived mononuclear fractions were separated extracted was amplified by PCR. RT-PCR showed that...

10.3109/10428194.2014.953150 article EN Leukemia & lymphoma/Leukemia and lymphoma 2014-09-24

The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability catalyze the breakdown L-tryptophan along L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, goal this study was investigate role as a prognostic marker for AML. We enrolled 48 AML patients. concentrations were measured by high-performance liquid chromatography. median serum level 1.67 μM. There no significant difference in complete remission rate...

10.3109/10428194.2015.1041388 article EN Leukemia & lymphoma/Leukemia and lymphoma 2015-04-24

Abstract Pirarubicin (tetrahydropyranyl adriamycin [THP]) is an anthracyclin with less cardiotoxicity than doxorubicin (DOX). We previously reported the efficacy and safety of R‐THP‐COP consisting rituximab (R), THP, cyclophosphamide (CPA), vincristine (VCR), prednisolone (PSL) for diffuse large B cell lymphoma (DLBCL) in phase 2 studies. Here, we prospectively compared standard R‐CHOP regimen (consisting R, CPA, DOX, VCR, PSL) a noninferiority 3 trial. This prospective, randomized study...

10.1002/hon.2524 article EN Hematological Oncology 2018-06-08

Indoleamine 2,3-dioxygenase (IDO), a tryptophan-catabolizing intracellular enzyme of the L-kynurenine pathway, causes preneoplastic cells and tumor to escape immune system by inducing tolerance; this mechanism might be associated with development progression human malignancies. In present study, we investigated role IDO in diethylnitrosamine (DEN)-induced hepatocarcinogenesis using IDO-knockout (KO) mice. To induce hepatocellular carcinoma (HCC), hepatic adenoma, lesions termed foci cellular...

10.1371/journal.pone.0146279 article EN cc-by PLoS ONE 2016-01-04

The controlling nutritional status (CONUT) score is a simplified index calculated from serum albumin, total cholesterol, and lymphocyte count. This study evaluated the prognostic impact of CONUT on overall survival (OS) in patients with peripheral T-cell lymphoma (PTCL). A multicenter, retrospective cohort including 99 PTCL was conducted. significantly higher non-survivor group (median 5, range 0-12) than survivor 3, 0-11; p = 0.026). an independent factor multivariable Cox proportional...

10.1080/10428194.2021.2020777 article EN cc-by-nc-nd Leukemia & lymphoma/Leukemia and lymphoma 2021-12-29

Objectives: Presepsin (PSEP: soluble CD14 subtype) is produced from bacteria-stimulated monocytes or neutrophils, thus recognized as a biomarker of sepsis. Aberrant functions in monocyte neutrophils are increasingly systemic lupus erythematosus (SLE). We investigated whether plasma PSEP reflects disease activity patients with SLE. Methods: This retrospective study comprised 35 SLE and 72 non-SLE autoimmune diseases who visited our facility during the period August 2012 to September 2015....

10.1080/14397595.2017.1408755 article EN Modern Rheumatology 2017-12-14

Abstract Naked mole rats (NMRs) have extraordinarily long lifespans and anti-tumorigenic capability. Recent studies of humans mice shown that many age-related diseases, including cancer, are strongly correlated with immunity, macrophages play particularly important roles in immune regulation. Therefore, NMR may contribute to their unique phenotypes. However, the limited by material restrictions lack an established experimental strategy. In this study, we developed a flow cytometric strategy...

10.1038/s41598-019-54442-1 article EN cc-by Scientific Reports 2019-11-29

Abstract The CHOP regimen consisting of cyclophosphamide, doxorubicin (DOX), vincristine and prednisolone has been the most used for peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS). Pirarubicin [tetrahydropyranyladriamycin (THP)], a derivative DOX, is an anthracycline with reportedly less cardiotoxicity than DOX. Here, we confirmed efficacy THP‐COP using THP instead DOX in treatment PTCL‐NOS. study protocol employed retrospective, consecutive entry design. We retrospectively...

10.1002/hon.2262 article EN Hematological Oncology 2015-10-09

This study investigated the prognostic impact of vitamin D deficiency and reduced skeletal muscle mass in diffuse large B-cell lymphoma (DLBCL) patients. A retrospective analysis 186 newly diagnosed DLBCL patients from 2012 to 2022 was conducted, measuring serum 25-hydroxyvitamin [25(OH)D] levels index (SMI). Decreased were linked more severe disease, with a median 25(OH)D concentration 13 (4.0-27) ng/mL. Males group low SMI had considerably lower concentration. The optimal threshold for...

10.3390/nu16162653 article EN Nutrients 2024-08-11

Management of constipation in patients receiving cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) or CHOP-like chemotherapy regimens is important for prevention paralytic ileus. We reported earlier that the laxative action magnesium oxide reversed by concomitant use antacids cancer opioid analgesics. Here, we assessed prevalence prophylactic medication control CHOP non-Hodgkin's lymphoma. Data obtained from 211 eligible were retrospectively analyzed. Almost all (99%)...

10.1248/bpb.b16-01001 article EN Biological and Pharmaceutical Bulletin 2017-01-01

We have reported the efficacy of salvage chemotherapy P-IMVP16/CBDCA for patients with diffuse large B cell lymphoma (DLBCL) who had previously received CHOP before availability rituximab (R). Here, we confirmed R combined as a DLBCL, R-CHOP. retrospectively analysed 59 relapse or refractory DLBCL (38 male and 21 female patients) presenting between June 2004 2013. The 375 mg/m2 on day 1, methylprednisolone 1000 mg/body 3 days (from to 5), ifosfamide 5 7), methotrexate 30 12, etoposide 80...

10.1002/hon.2285 article EN Hematological Oncology 2016-03-21

Predicting prognosis is crucial in older patients with diffuse large B-cell lymphoma (DLBCL). This study evaluated the prognostic impact of controlling nutritional status (CONUT) score, a simple index, for DLBCL (≥65 years age) treated R-CHOP-like regimens retrospective, cohort including 203 patients. The CONUT score was an independent factor overall survival (hazard ratio 1.11, 95% confidence interval (CI) 1.01-1.21, p = 0.032) multivariable Cox proportional hazards model. On...

10.1080/10428194.2023.2295787 article EN Leukemia & lymphoma/Leukemia and lymphoma 2023-12-20

Abstract Indoleamine 2,3‐dioxygenase exerts intense immunomodulatory effects due to enzymatic activities that catalyze the breakdown of essential amino acid l ‐tryptophan. The activity indoleamine can be estimated by measuring serum ‐kynurenine concentrations. Here, we aimed determine role as a prognostic factor for peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS) in retrospective analysis data derived from 31 consecutive patients between June 2000 and March 2013 who were...

10.1002/hon.2318 article EN Hematological Oncology 2016-06-24

We compared the predictive ability of International Prognostic Index (IPI), a frequently used prognostic model for peripheral T-cell lymphoma (PTCL), with that type-specific model, PTCL-U (PIT). retrospectively analyzed 113 patients diagnosed PTCL. The median age was 67 years (range, 16-88 years), 75 (66%) were male, and most common disease type PTCL, not otherwise specified (69%). With follow-up 6.8 (interquartile range, 2.7-9.9 5-year survival rates four groups in IPI 85%, 62%, 49%, 13%,...

10.1038/s41598-023-46501-5 article EN cc-by Scientific Reports 2023-11-04

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with patients exhibiting wide range of outcomes.Many investigators have searched for prognostic factors DLBCL and, recently, the concentrations several cytokines were identified to predict clinical outcome aggressive non-Hodgkin's lymphomas, including DLBCL.Tumor necrosis factor receptor 1 (TNFR1), which member TNFR superfamily, has soluble form (sTNFR1).In this study, we focused on sTNFR1 as candidate that can be measured...

10.3960/jslrt.54.117 article EN Journal of Clinical and Experimental Hematopathology 2014-01-01

Concurrent seminoma and malignant lymphoma of the testis is rare. We present a case concurrent peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) in 54-year-old man who complained painless left testicular enlargement. Radical orchiectomy was performed. Macroscopically, tumor (4.0 × 3.0 cm) creamy, soft, homogeneous, microscopic evaluation revealed an alveolar structure large cells that formed sheets, as well colonization by other abnormal 1.0 cm area. The portion comprising...

10.3960/jslrt.55.169 article EN Journal of Clinical and Experimental Hematopathology 2015-01-01

The sternoclavicular joint is a diarthrodial that can be involved in rheumatoid arthritis (RA), and detectable by ultrasound (US) examination 15% of patients with RA1. Methotrexate-related lymphoproliferative disorder (MTX-LPD) occurs extranodal sites about 40%–50% the affected patients2; however, intraarticular MTX-LPD very rare manifestation only 1 case report occurring knee joint3 …

10.3899/jrheum.160401 article EN The Journal of Rheumatology 2016-11-01
Coming Soon ...